The Molecular Neuroscience Research Center (MNRC) was founded in 1989 as the first research center at Shiga University of Medical Science. The center comprises the Neurology Unit, Clinical Research Unit, and Translational Research Unit.

We have spearheaded pioneering research in the pathophysiology of dementia and neurodegenerative diseases, advancing amyloid MRI with fluorine compounds, antibody therapy for ALS, antisense oligonucleotide therapeutics targeting tau, and the development of biomarkers. Our work, marked by originality and impact, has been shared widely across the globe. Moving forward, we will enhance our collaborative efforts within each unit and extend our interactions with international and domestic organizations.

About 25 years ago, when I started my journey in medicine, we were up against major challenges like cancer, AIDS, and neurodegenerative diseases to overcome. Thanks to incredible progress in specific molecular targeted therapies, genomic medicine, and diagnostic technologies we’ve made great strides in managing cancer and HIV. Now, we’re turning our attention to neurodegenerative diseases. Although the development of antibody drugs for Alzheimer’s disease represents a significant advancement, treating most neurodegenerative diseases remains a formidable challenge. Our knowledge of diseases like Alzheimer’s, Parkinson’s, and ALS has grown a lot by studying how certain proteins and genes play a role in these conditions.

Looking ahead, it’s crucial to use a mix of research tools – like MRI scans, data from wearable tech, and genetic information – to better understand these diseases and find effective treatments and ways to detect them early. The Molecular Neuroscience Research Center (MNRC) at Shiga University of Medical Science is dedicated to advancing our comprehension of these complex diseases and pioneering new therapeutics. We are committed to innovative research, driven by a spirit of creativity and autonomy.